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ABSTRACT 
Objective To examine if the beneficial effect of statin medication on mortality seen in 
randomised clinical trials of type 2 diabetes, applies equally to observational studies in the 
general population of older people.  
Design A prospective, population-based cohort study.  
Setting Reykjavik, Iceland.  
Participants 5152 men and women from the Age, Gene/Environment Susceptibility - 
Reykjavik study, mean age 77 years, range of 66-96 years. 
Main outcome measure Cardiovascular and all-cause mortality rates and the relative risk 
of dying according to statin use and history of coronary heart disease (CHD) in persons 
with type 2 diabetes and those without diabetes with a median follow up time of 5.3 years, 
until end of 2009.  
Results The prevalence of type 2 diabetes was 12.4% of which 35% used statins. Statin 
use was associated with a 50% (95% confidence interval 8% to 72%) lower cardiovascular 
mortality and 53% (29% to 68%) lower all-cause mortality rates in persons with diabetes. 
For those without diabetes, statin use was associated with a 16% (-24% to 43%) lower 
cardiovascular and 30% (11% to 46%) lower all-cause mortality rates. Persons with 
diabetes using statins had a comparable risk of cardiovascular and all-cause mortality as 
the general population without diabetes. The effect was independent of the level of 
glycemic control. 
Conclusion This observational study lends important support to existing data from 
randomised clinical trials. Our data suggest that in the general population of older people 
with diabetes, statin medication markedly reduces the excess cardiovascular and all-cause 
mortality risk, irrespective of the presence or absence of CHD or glucose-lowering 
medication.  
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Article focus 
• Clinical trials have shown that statin medication is beneficial for persons with 
diabetes as regards cardiovascular morbidity and mortality.  
• This is not well established except within the rigours of randomised clinical studies. 
Key message 
• This population-based observational study of older individuals demonstrates that 
treatment with statins in persons with diabetes reduces cardiovascular mortality rate 
to a level comparable to what is observed in those without diabetes.  
• The effect observed is of comparable magnitude to the effect reported in 
randomised clinical trials. 
Strengths and limitations of this study 
• A major strength of the study is the proportionally large national representation in 
this population-based cohort, the high participation rate and the comprehensive 
information on morbidity and mortality. The effect observed is of comparable 
magnitude to the effect reported in randomised clinical trials. 
• A limitation is the non-attendance of frail individuals in the study that may cause a 
possible bias. Non-attendees in the study have been shown, however, at earlier 
visits to have comparable levels of conventional cardiovascular risk factors. A 
weakness in our study is the relatively low number of events during the five-year 
follow-up. 
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Abbreviations 
AGES-Reykjavik, Age, Gene/Environment Susceptibility - Reykjavik Study; BMI, body 
mass index; BP, blood pressure; CABG, coronary artery bypass graft; CHD, coronary heart 
disease; 95% confidence interval, 95%CI; CRP, C-reactive protein; CVD, cardiovascular 
disease;  HbA1c, haemoglobin A1c; ICD-9 and ICD-10, International Statistical 
Classification of Diseases and Related Health Problems 9th and 10th  Revision; MI, 
myocardial infarction; PCI, percutaneous transluminal coronary intervention; SD, standard 
deviation; TG, triglycerides; WHO, World Health Organization 
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INTRODUCTION  
The excess risk of vascular disease in persons with diabetes is about twofold compared 
with those without diabetes and is independent of other conventional cardiovascular risk 
factors. This was clearly demonstrated in the meta-analysis from 102 prospective trials, 
recently published by the Emerging Risk Factors Collaboration1.  The beneficial effects of 
statins in reducing major vascular events in patients with diabetes, irrespective of their 
baseline lipid levels, have been demonstrated in a number of randomised clinical trials2- 5.  
Additionally, improved life expectancy in recent years of persons with type 2 diabetes, 
relative to those without diabetes, has been reported6-8, although a difference still exists. 
This improvement is possibly a result of better adherence to published clinical guidelines, 
advocating aggressive multifactorial treatment9.  However, many patients with type 2 
diabetes are still not receiving treatment with statin medication10, 11  
Although randomised clinical trials have clearly demonstrated the benefit of statin 
use with regard to cardiovascular morbidity and mortality, every physician will daily face 
the question whether these trial results apply to his patient. A general population of 
individuals, with a varied background of co-morbidities which may or may not have 
excluded them from participation, is not fully represented in the aforementioned trials. This 
is why it is of key importance to gather confirmatory information from population-based 
observational studies. One recent prospective population-based study10 from the U.K. 
General Practice Database has indeed reported the beneficial effect of statin treatment in 
lowering all-cause mortality in type 2 diabetes.  Older persons are under-represented in 
clinical trial data and it is therefore particularly important to obtain information on the 
potential improvement in life expectancy with statin use in older persons with type 2 
diabetes, as well as data on the relative impact of lipid lowering treatment in that age 
group. This will help in clarifying at a population-based level whether current guidelines 
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should be applied to older persons, who may have had diabetes for an extended period of 
time. 
The present study addresses this information gap by exploring treatment modalities 
and cardiovascular and total mortality in older individuals with diabetes in the population-
based Age, Gene/Environment Susceptibility (AGES)-Reykjavik study. 
 
METHODS 
Study population 
Between 2002 and 2006 the AGES-Reykjavik study re-examined 5764 unselected 
survivors of the original cohort who had previously participated in the Reykjavik Study12. 
In the present study 5152 of these survivors are included, with a mean age of 77 years 
(range 66-96) and a median follow up time of 5.3 years. Informed consent was obtained 
from all study participants. The Reykjavik Study cohort originally comprised a random 
sample of 30 795 men and women born in 1907–1935, living in Reykjavik in 1967 that 
were invited to participate in a long-term prospective cardiovascular survey. A total of 19 
381 attended, resulting in 71% recruitment rate 12.  
As part of the baseline examination in the AGES-Reykjavik study, a 
comprehensive questionnaire was administered. In order to eliminate any persons with type 
1 diabetes in the study, participants reporting onset of diabetes before the age of 40 were 
not included; neither were participants not completing their questionnaire or having 
incomplete data for other study variables included: 66 had missing data about diabetes 
history on questionnaire; 21 were considered to have diabetes of type 1; 78 had missing 
data on risk factors (cholesterol, systolic blood pressure, body mass index, triglycerides); 
447 had missing HbA1c.  Participants were asked to bring all medications and supplements 
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used in the previous 2 weeks to the clinic. All participants also had a fasting blood 
specimen drawn and analysed as documented below. 
The criteria used for type 2 diabetes diagnosis was either fasting serum glucose of 
≥7mmol/l at the visit to the clinic, based on the WHO recommendations from 199913, self-
reported diabetes in the questionnaire and/or use of diabetes medication. 
Blood samples were drawn after overnight fasting. Total cholesterol, HDL 
cholesterol, triglycerides, high sensitivity CRP, glucose and HbA1c were analysed on a 
Hitachi 912, using reagents from Roche Diagnostics and following the manufacturer’s 
instructions. LDL was calculated using the Friedewald equation14. 
Blood pressure was measured with a mercury sphygmomanometer with a large 
cuff, and the mean value of two consecutive blood pressure measurements was used in the 
analysis. Height and weight were measured and BMI calculated as kg/m2. 
Information on the causes of death was based on data from a complete registry of 
deaths available from the Icelandic National Roster. All-cause mortality was defined 
according to ICD 9-10. In this study we calculated an individual's time at risk from the date 
of participation in the baseline survey until the date of death from cardiovascular disease 
(ICD-9 and ICD-10: defined as in the SCORE project15) or from all causes, or until the end 
of follow-up in the cohort. The information is collected from National Health System 
Records by the Icelandic Heart Association. 
The study was approved by the National Bioethics Committee in Iceland (VSN 00-
063) as well as the Institutional Review Board of the Intramural Research Program of the 
National Institute on Aging and the Data Protection Authority in Iceland.  
 
Statistical analyses  
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Baseline characteristics of participants by sex and diabetic status in the AGES-Reykjavik 
study were compared using either linear or logistic regression with age adjustment. 
Skewed variables were log-transformed.  The Cox proportional hazards regression model 
was used to estimate mortality rates and hazard ratios for the effect of risk factors and 
statin use.  The time on study was used as the time scale. For hazard ratio estimates, an 
adjustment was made for age and sex in a simple model, and additionally for the following 
cardiovascular risk factors: cholesterol, HDL-cholesterol, systolic blood pressure, BMI, 
triglycerides, CRP, hypertensive medication, and current smoking. A separate term was 
used in the survival models to represent subgroups, formed by diabetes, history of CHD 
and statin use.  The mortality rate was estimated from the average of the cumulative hazard 
function after a five-year follow-up and represented as the rate per 1000 person-years.  The 
proportionality assumption for the hazard ratio associated with type 2 diabetes was 
inspected graphically and by testing the significance of the interaction of type 2 diabetes 
statuses with the logarithm of the follow-up of time analysed as a time-dependent 
covariate. Significance testing was two-sided and based on a 5% probability level. We 
analysed the data using SAS/STAT® software, version 9.2. 
 
RESULTS 
The mean age of the 5152 AGES-Reykjavik study participants was 77.0 (±5.8) years, with 
an age range of 66-96 years. The baseline characteristics in men and women with and 
without type 2 diabetes according to statin use are shown in Table 1. A higher percentage 
of individuals with type 2 diabetes were hypertensive than those without diabetes; they 
also had lower HDL-cholesterol but higher triglycerides and BMI, irrespective of statin 
use. Statin medication reduced the mean level of total and LDL-cholesterol similarly in 
those with and without diabetes, or by about 1.2 mmol/l in both men and women. In statin 
Page 8 of 26
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
group.bmj.com on June 4, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
For peer review only
 
9 
 
users CRP was lower by 0.30 mg/l in men and 0.50 mg/l in women without diabetes and 
0.80 and 1.05 mg/l respectively in those with diabetes. The prevalence of coronary heart 
disease estimated from hospital records in persons without diabetes using statins, was 
71.1% in men and 34.4% in women compared to 7.9% and 2.2% respectively in those not 
using statins. In individuals with diabetes the coronary heart disease prevalence was 59.4% 
in men and 24.2% in women using statins, compared to 14.8% and 8.6% respectively in 
those not on statins. Over 93% of all statin users were hypertensive compared to 78% of 
non-statin users. 
The prevalence of type 2 diabetes and use of glucose lowering treatment in men 
and women is shown in Table 2. About 16% of men and 9.5% of women in the cohort had 
type 2 diabetes and the proportion of persons with diabetes undiagnosed at baseline was 
31%. In the group with previously diagnosed type 2 diabetes, 23% of the men and 35% of 
the women controlled their blood sugar level with diet only. As shown in Table 2, less than 
7% of persons with diagnosed diabetes were simultaneously taking 3 or 4 drugs for 
lowering blood glucose. For participants with a prior diagnosis of diabetes, the average 
time from diagnosis at baseline assessment was just over 10 years. 
 
Effect of statins on cardiovascular and all-cause mortality     
The five-year average cardiovascular disease mortality and all-cause mortality rates for 
those with and without diabetes are shown in Figure 1. Mortality rate is estimated 
according to statin use and prevalence of coronary heart disease, adjusted to age 75, sex 
and the mean levels of cardiovascular risk factors (cholesterol, HDL-cholesterol, systolic 
blood pressure, BMI, triglycerides, hypertensive medication and current smoking) within 
each cohort. About 26% of men and 16% of women without diabetes and about 35% in 
both sexes with diabetes were statin users. Statin medication was administered to 69.2% of 
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persons with prevalent coronary heart disease and known diabetes compared to 31.6% of 
those with known diabetes but without coronary heart disease (Supplement Table 1). 
For individuals with diabetes and prevalent coronary heart disease, statin use was 
associated with a significantly lower rate of cardiovascular disease mortality (Figure 1a) 
compared to those not using statins, or 11.3 vs. 24.6 per 1000 person years. This amounts 
to 54% (95% confidence interval 14% to 75%) lower mortality rate in statin users. 
Similarly statin use was associated with an all-cause mortality rate of 27.8 vs. 63.3 per 
1000 person years when comparing the same two groups (Figure 1b), amounting to 55% 
(31% to 71%) lower mortality rate in statin users.  In individuals with diabetes but without 
coronary heart disease, the rate was 48% (1% to 73%) lower for cardiovascular disease 
mortality and 52% (26% to 69%) lower for all-cause mortality in the group using statins 
compared to non-statin users. Combining the groups the hazard of cardiovascular disease 
mortality was 50% lower in statin users compared to non-statin users and all-cause 
mortality was 53% lower (Supplement Table 2). 
Statin use was associated with 16% (-24% to 43%) lower mortality rate in 
individuals without diabetes as shown in Figure 1, albeit not statistically significant. For 
all-cause mortality statin users had 30% (11% to 46%) lower mortality rate than in non-
statin users.  
The effect of statins was not modified by the level of HbA1c, the use of oral 
hypoglycaemic or hypertensive medication, or whether the diabetes was prevalent or newly 
diagnosed (Supplement Figures 1 and 2).  
The dramatic effect of statin medication use on mortality rate in persons with 
diabetes is also reflected in the hazard ratios for the relative risk of cardiovascular and all-
cause mortality in individuals with diabetes compared to those without as shown in Table 
3. In persons with diabetes and prevalent coronary heart disease not on statins, the relative 
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risk of dying from cardiovascular disease was 3.33 (2.05 to 5.50) when compared to those 
without diabetes, after adjusting for age, sex and cardiovascular risk factors. The 
individuals treated with statins, however, had a relative risk of 1.51 (0.83 to 2.75). In 
persons with diabetes but without coronary heart disease not on statins, the relative risk 
was 1.40 (1.03 to 1.89) compared to 0.71 (0.31 to 1.62) for those on statins.  Adding CRP 
to the risk factor adjustment showed minimal attenuation of the hazard ratios (Table 3). 
This implies that the protective effect of statins is not solely attributable to the effect on 
these cardiovascular risk factors. 
 
DISCUSSION 
The major finding in our population-based AGES-Reykjavik study of older individuals 
with diabetes is the marked improvement in survival associated with statin medication 
when compared to those not receiving statins, both with respect to cardiovascular and all-
cause mortality. This is independent of prevalent coronary heart disease or glucose-
lowering treatment, reducing the mortality rate in individuals with diabetes to a level 
comparable to those without diabetes.  
Statin medication in diabetes has increased gradually during the last decade. Data 
from the U.K. General Practice Research Database showed an increase in statin use from 
about 5% in 1996 to 63.5% in women and 71.0% in men in 200510, which was associated 
with hazard ratios of mortality of 0.29 in women and 0.34 in men in the first two years 
following diagnosis of diabetes. Similarly, in Denmark, only 7% of patients receiving 
glucose-lowering medication also received statins in 1997, but this had increased to 62% in 
200711; information on mortality in that study is however lacking. In our cohort of older 
persons with diabetes the prevalence of statin medication use was 35% overall. In those 
with known diabetes but without coronary heart disease the prevalence of statin medication 
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use was 31.6%, but 11.6% in the newly diagnosed without coronary heart disease. One 
may speculate if this low prevalence of statin use is due to Icelandic physicians’ 
unawareness of results from recent clinical trials or simply their belief that the evidence 
does not apply to older patients in general. 
It is of course well recognised that statin treatment favourably impacts vascular 
event rates in both those with and without diabetes. In the Heart Protection Study2 for 
example it was concluded that 40 mg of simvastatin daily would probably reduce the rate 
of first major vascular event by about a third. Similarly a two-year treatment period with 
atorvastatin in type 2 diabetes in the CARDS study reduced the death rate by 27%, 
prompting an early termination of the trial16. The authors concluded that lipid-lowering 
treatment should at least receive the same attention as glycemic and blood pressure control 
in type 2 diabetes patients without a history of cardiovascular disease, which is in harmony 
with current clinical guidelines. Aggressive multifactorial treatment of high-risk 
individuals with type 2 diabetes has been shown to be important9, and may also be 
appropriate for persons diagnosed above the age of 70. Recent results from several large 
studies17, 18 have, however, indicated that caution may be needed as regards aggressive 
glucose lowering treatment in those with long-established coronary heart disease and 
diabetes of long duration. In our study, statin use at baseline, but not use of glucose-
lowering medication, is associated with the marked reduction of cardiovascular and total 
mortality rate, reducing mortality in those with diabetes to a level similar to those without 
diabetes.   
Statin medication under the rigors of controlled study conditions in selected 
individuals has thus been shown to be helpful2, 4 5. The novelty of our study is that statin 
medication also is very likely to be important in older persons in the community, persons 
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which may or may not fit the stringent criteria of normality imposed for inclusion into 
randomised clinical trials.   
Recently a large meta-analysis1 demonstrated that the increased cardiovascular 
mortality seen in type 2 diabetes is not explained by conventional cardiovascular risk 
factors. This suggests that the effect of the statins on cardiovascular mortality seen in our 
population-based cohort may reach beyond the statins' effect on cholesterol levels, possibly 
by reducing the damaging effect of inflammatory agents19, 20. Inflammation as measured by 
CRP, however, does not appear to be the explanation in our study, as adjusting for CRP in 
the risk models did not attenuate the relative risk although those on statins had markedly 
lower CRP. This warrants further study. 
The prevalence of diabetes in Iceland is changing in the same fashion as in other 
western societies21. Furthermore, the Icelandic population is similar to other western 
populations with respect to cardiovascular morbidity and mortality22, and our results are 
therefore applicable to other Caucasian populations. Thus, considerable additional benefit 
can be expected by adhering to the current guidelines on statin use in treating individuals 
with diabetes, also in the older age-groups.  
In summary, we have estimated the risk of death from cardiovascular disease and 
from all causes in a population-based cohort of older persons with type 2 diabetes. The 
main finding is that statin use, irrespective of glucose-lowering and antihypertensive 
medication, eliminates the difference in the mortality rate of older persons with type 2 
diabetes, compared to those without diabetes. Our study suggests that treatment with 
statins is paramount in the multifaceted management of type 2 diabetes. Strict adherence to 
the current guidelines is therefore of key importance for older persons with diabetes, 
regardless of the presence or absence of cardiovascular disease or the level of glucose or 
blood pressure control.  
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Our results urgently call for other population-based studies with comparable 
information to confirm the effect of statin use on mortality in individuals with type 2 
diabetes. 
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Table 1. Baseline characteristics according to statin use in men and women without and with type 2 
diabetes (T2D). The AGES-Reykjavik study from 2002-2006. 
 
 
Men    Women    
 
        
Variables Statins no  Statins yes  Statins no  Statins yes  
 
(mean ± SD, IQR or %) without T2D with T2D without T2D with T2D without T2D with T2D without T2D with T2D 
(number) (1357) (230) (477) (128) (2237) (186) (442) (95) 
Age in years 77.4  (±5.8) 77.9  (±6.1)  76.0  (±4.8)  75.5  (±4.4)  77.0  (±6.1) 78.7  (±6.0) ***  76.1  (±4.8)  76.3  (±4.5) 
Cholesterol mmol/l 5.57  (±0.93) 5.38  (±0.98) ** 4.32  (±0.82)  4.14  (±0.84) * 6.19 (±1.05) 5.97  (±1.01) **  4.96  (±0.83) 4.67  (±0.94) ** 
HDL cholesterol mmol/l 1.46  (±0.40) 1.26  (±0.34) *** 1.40  (±0.37)  1.26  (±0.33) ***  1.75  (±0.45) 1.53  (±0.41) ***  1.70  (±0.40) 1.48  (±0.41) ***  
LDL cholesterol mmol/l 3.61  (±0.85) 3.40  (±0.89) **  2.38  (±0.67)  2.21  (±0.68) **  3.90  (±0.98) 3.73  (±0.91) *  2.71  (±0.72) 2.41  (±0.70) ***  
TG mmol/l, median (IQR) 0.97  (0.56) 1.33  (0.83) ***  1.01  (0.65) 1.29  (0.98) ***  1.04  (0.63) 1.38  (0.85) *** 1.11  (0.67) 1.57 (0.85) ***  
CRP mg/l, median (IQR)  1.90 (2.70) 2.20 (3.53) ** 1.60  (2.20)  1.40  (2.10)  2.00 (3.20) 3.15 (5.65) ***  1.50  (2.10) 2.10  (3.30) * 
BMI kg/m2 26.4  (±3.7) 28.3  (±4.2) *** 27.0  (±3.7)  28.4  (±3.7) ***  27.0  (±4.9) 29.0  (±5.5) ***  26.8  (±4.0) 30.2  (±5.1) *** 
Systolic BP mm Hg 142.9  (±20.6) 141.1  (±20.7) 144.1  (±20.3) 148.2  (±19.6) ***  142.2  (±21.0) 143.3 3  (±21.8)  143.3  (±20.2) 143.6  (±19.7)   
Diastolic BP mm Hg 77.0  (±9.4) 74.7  (±10.8) ** 74.4  (±9.7)  74.6  (±10.3)  72.6  (9.3) 70.5  (±10.5)* 71.6  (±10.2) 69.7  (±8.9)  
Hypertension %† 73.5 88.7 *** 91.6 95.3 78.9 88.7 ** 92.5 95.8  
Hypertensive  medication % 50.0 75.2 *** 85.5 87.5 58.7 79.6***  84.6 90.5  
Glucose lowering medication - 46.1 - 64.1 - 36.6 - 64.2 
CHD prevalence %‡ 7.9 14.8** 71.1 59.4* 2.2 8.6***  34.4 24.2* 
Family history MI % 30.1 39.1 ** 45.2 41.4 40.2 51.6 ** 56.7 53.7 
Sports current % 51.0 43.9  54.3 45.3  47.1 40.9  50.7 36.8*  
Smoking % 11.9 12.2  9.0 9.4 12.4 10.2  12.9 9.5 
Haemoglobin A1c  % 5.54 (±0.33) 6.38 (±0.88) ***  5.58 (±0.32) 6.55 (±0.79) ***  5.61 (±0.33) 6.32 (±0.95) ***  5.64 (±0.34) 6.58 (±0.88) *** 
Glucose mmol/l 5.57 (±0.50) 7.95 (±2.09) ***  5.58 (±0.53) 7.92 (±2.19) ***  5.44 (±0.51) 7.60 (±2.00) ***  5.41  (±0.52) 7.97  (±2.38) ***  
Significance estimates for age-adjusted comparison between those with and without T2D and not using statins (no) and statin users (yes): *p<.05; **p<.01; *** p<.001.  
†Hypertensive are those with systolic BP>140 mmHg, diastolic BP>90 mmHG or on hypertensive medication. 
 
‡Prevalence from history of MI, PCI, and CABG in hospital records. 
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Table 2.  Prevalence of type 2 diabetes (T2D) and glucose lowering treatment in the 
AGES-Reykjavik study 2002-2006. 
AGES-Reykjavik study   Men Women Men and 
women 
% of total T2D
Total T2D at baseline % (n) 16.3 (358) 9.5 (281) 12.4 (639) 100 
Diagnosed at study entry % (n) 5.1 (113) 2.8 (84) 3.8 (197) 31 
With prevalent T2D at study entry % (n) 11.2 (245) 6.7 (197) 8.6 (442) 69 
Mean T2D duration in years (±SD)   10.7 (±10.0)  
    
 
Glucose lowering treatment in prevalent 
T2D 
   
 
        on special diet only % (n) 23.3 (57) 34.5 (68)   
        on diabetic medication % (n) 76.7 (188) 65.5 (129)   
thereof using 1 drug % (n)  43.7 (107) 40.1 (79)  
 
"     using 2 drugs % (n) 25.7 (63)  19.8 (39)  
 
"     using 3 drugs % (n) 6.9 (17) 4.6 (9)  
 
"     using 4 drugs % (n) 0.4 (1) 1.0 (2)  
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Table 3.  Hazard ratios (HR) for the relative risk of cardiovascular disease (CVD) mortality and all cause mortality in people with type 2 diabetes (T2D) 
compared to all non-diabetics according to prevalent coronary heart disease (chd) and statin use*.  The AGES-Reykjavik study from 2002-2006.   
 
  
 
 Adjusted for age and sex  Adjusted for age, sex,  Adjusted for age, sex,  
 
   and †CVD risk factors †CVD risk factors and CRP 
 
    
 
   
HR                      95% CI 
                 HR              95% CI        HR               95% CI 
Death from CVD     
     
All T2D  1.71 (1.35 to 2.17) 1.48 (1.15 to 1.90) 1.45 (1.13 to 1.86) 
According to chd and statin use:       
T2D with chd not on statins  4.71 (2.93 to 7.58) 3.33 (2.02 to 5.50) 3.20 (1.94 to 5.29) 
T2D with chd on statins  1.92 (1.08 to 3.43) 1.51 (0.83 to 2.75) 1.55 (0.85 to 2.82) 
T2D without chd and not on statins  1.53 (1.14 to 2.05) 1.40 (1.03 to 1.89) 1.34 (0.99 to 1.82) 
T2D without chd and on statins  0.83 (0.37 to 1.85) 0.71 (0.31 to 1.62) 0.75 (0.33 to 1.69) 
Death from all causes       
 
      
All T2D  1.44  (1.22 to 1.69) 1.35 (1.14 to 1.61) 1.32 (1.11 to 1.57) 
According to chd and statin use:       
T2D with chd not on statins 3.48 (2.43 to 4.99) 2.88 (1.98 to 4.18) 2.72 (1.87 to 3.95) 
T2D with chd on statins  1.61 (1.10 to 2.37) 1.34 (0.90 to 1.99) 1.37 (0.92 to 2.04) 
T2D without chd not on statins  1.34 (1.09 to 1.64) 1.34 (1.08 to 1.64) 1.27 (1.03 to 1.57) 
T2D without chd on statins  0.77 (0.46 to 1.28) 0.70 (0.42 to 1.17) 0.73 (0.44 to 1.23) 
*Individuals on statin medication are identified as on statins, those not on statin medication as not on statins. 
†CVD risk factors: cholesterol, HDL-cholesterol, systolic blood pressure, BMI, triglycerides, hypertensive medication, and current smoking.  
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Figure 1. a) Cardiovascular disease (CVD) mortality rate and b) all cause mortality rate 
per 1000 person years for subjects without type 2 diabetes (not T2D) and with type 2 
diabetes (T2D) according to statin use and prevalent coronary heart disease (chd).  Rates 
have been adjusted to age 75, sex and the mean levels of cardiovascular risk factors 
(cholesterol, HDL-cholesterol, systolic blood pressure, BMI, triglycerides, hypertensive 
medication and current smoking) within each cohort.  Follow up was through 2009 (a 
median period of 5.3 years) for the AGES-Reykjavik study. The vertical lines represent the 
mortality rate of all without diabetes (not T2D, N=4513) 
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age 75, sex and the mean levels of cardiovascular risk factors (cholesterol, HDL-cholesterol, systolic 
blood pressure, BMI, triglycerides, hypertensive medication and current smoking) within each 
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STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology* 
Checklist for cohort, case-control, and cross-sectional studies (combined) 
Section/Topic Item # Recommendation Reported on page # 
(a) Indicate the study’s design with a commonly used term in the title or the abstract 1 Title and abstract 1 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 5 
Objectives 3 State specific objectives, including any pre-specified hypotheses 5 
Methods  
Study design 4 Present key elements of study design early in the paper 6 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data 
collection 
6 
(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe 
methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 
6 Participants 6 
(b) Cohort study—For matched studies, give matching crit ria and number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per case 
Not applicable 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic 
criteria, if applicable 
8-10 
Data sources/ measurement 8*  For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one group 
6-7 
Bias 9 Describe any efforts to address potential sources of bias Not done 
Study size 10 Explain how the study size was arrived at 6-7 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen 
and why 
7-8 
(a) Describe all statistical methods, including those used to control for confounding 7-8 
(b) Describe any methods used to examine subgroups and interactions Separate terms for 
subgroups in 
statistical models 
Statistical methods 12 
(c) Explain how missing data were addressed 6 
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(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy 
6 
(e) Describe any sensitivity analyses Not done 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-up, and analysed 
8 
  (b) Give reasons for non-participation at each stage 13 
  (c) Consider use of a flow diagram  
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and 
potential confounders 
8-9 
  (b) Indicate number of participants with missing data for each variable of interest 6 
  (c) Cohort study—Summarise follow-up time (eg, average and total amount) 6 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 8-10 
  Case-control study—Report numbers in each exposure category, or summary measures of exposure  
  Cross-sectional study—Report numbers of outcome events or summary measures  
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% 
confidence interval). Make clear which confounders were adjusted for and why they were included 
Table 3 
  (b) Report category boundaries when continuous variables were categorized  
  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Figure 1 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses All analyses are by 
subgroups 
Discussion  
Key results 18 Summarise key results with reference to study objectives 11-12 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction 
and magnitude of any potential bias 
13 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results 
from similar studies, and other relevant evidence 
12-13 
Generalisability 21 Discuss the generalisability (external validity) of the study results 13-14 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on 
which the present article is based 
14 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
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Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
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ABSTRACT 
Objective To examine if the beneficial effect of statin medication on mortality seen in 
randomised clinical trials of type 2 diabetes, applies equally to observational studies in the 
general population of older people.  
Design A prospective, population-based cohort study.  
Setting Reykjavik, Iceland.  
Participants 5152 men and women from the Age, Gene/Environment Susceptibility - 
Reykjavik study, mean age 77 years, range of 66-96 years. 
Main outcome measure Cardiovascular and all-cause mortality rates and the relative risk 
of dying according to statin use and history of coronary heart disease (CHD) in persons 
with type 2 diabetes and those without diabetes with a median follow up time of 5.3 years, 
until end of 2009.  
Results The prevalence of type 2 diabetes was 12.4% of which 35% used statins. Statin 
use was associated with a 50% (95% confidence interval 8% to 72%) lower cardiovascular 
mortality and 53% (29% to 68%) lower all-cause mortality rates in persons with diabetes. 
For those without diabetes, statin use was associated with a 16% (-24% to 43%) lower 
cardiovascular and 30% (11% to 46%) lower all-cause mortality rates. Persons with 
diabetes using statins had a comparable risk of cardiovascular and all-cause mortality as 
the general population without diabetes. The effect was independent of the level of 
glycemic control. 
Conclusion This observational study lends important support to existing data from 
randomised clinical trials. Our data suggest that in the general population of older people 
with diabetes, statin medication markedly reduces the excess cardiovascular and all-cause 
mortality risk, irrespective of the presence or absence of CHD or glucose-lowering 
medication.  
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Article focus 
• Clinical trials have shown that statin medication is beneficial for persons with 
diabetes as regards cardiovascular morbidity and mortality.  
• This is not well established except within the rigours of randomised clinical studies. 
Key message 
• This population-based observational study of older individuals demonstrates that 
treatment with statins in persons with diabetes reduces cardiovascular mortality rate 
to a level comparable to what is observed in those without diabetes.  
• The effect observed is of comparable magnitude to the effect reported in 
randomised clinical trials. 
Strengths and limitations of this study 
• A major strength of the study is the proportionally large national representation in 
this population-based cohort, the high participation rate and the comprehensive 
information on morbidity and mortality. The effect observed is of comparable 
magnitude to the effect reported in randomised clinical trials. 
• A limitation is the non-attendance of frail individuals in the study that may cause a 
possible bias towards more healthy individuals at baseline of this study. Non-
attendees in the study have been shown, however, at earlier visits to have 
comparable levels of conventional cardiovascular risk factors. A limitation is the 
unavailability of dietary information for this analysis. A weakness in our study is 
the relatively low number of events during the five-year follow-up. A limitation is 
the lack of glucose tolerance test for diagnosis of diabetes. 
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Key words   Cohort study, type 2 diabetes, statins, older persons, cardiovascular disease 
mortality, AGES-Reykjavik                       
 
 
Abbreviations 
AGES-Reykjavik, Age, Gene/Environment Susceptibility - Reykjavik Study; BMI, body 
mass index; BP, blood pressure; CABG, coronary artery bypass graft; CHD, coronary heart 
disease; 95% confidence interval, 95%CI; CRP, C-reactive protein; CVD, cardiovascular 
disease;  HbA1c, haemoglobin A1c; ICD-9 and ICD-10, International Statistical 
Classification of Diseases and Related Health Problems 9th and 10th  Revision; MI, 
myocardial infarction; PCI, percutaneous transluminal coronary intervention; SD, standard 
deviation; TG, triglycerides; WHO, World Health Organization 
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INTRODUCTION  
The excess risk of vascular disease in persons with diabetes is about twofold compared 
with those without diabetes and is independent of other conventional cardiovascular risk 
factors. This was clearly demonstrated in the meta-analysis from 102 prospective trials, 
recently published by the Emerging Risk Factors Collaboration1.  The beneficial effects of 
statins in reducing major vascular events in patients with diabetes, irrespective of their 
baseline lipid levels, have been demonstrated in a number of randomised clinical trials2- 5.  
Additionally, improved life expectancy in recent years of persons with type 2 diabetes, 
relative to those without diabetes, has been reported6-8, although a difference still exists. 
This improvement is possibly a result of better adherence to published clinical guidelines, 
advocating aggressive multifactorial treatment9.  However, many patients with type 2 
diabetes are still not receiving treatment with statin medication10, 11  
Although randomised clinical trials have clearly demonstrated the benefit of statin 
use with regard to cardiovascular morbidity and mortality, every physician will daily face 
the question whether these trial results apply to his patient. A general population of 
individuals, with a varied background of co-morbidities which may or may not have 
excluded them from participation, is not fully represented in the aforementioned trials. This 
is why it is of key importance to gather confirmatory information from population-based 
observational studies. One recent prospective population-based study10 from the U.K. 
General Practice Database has indeed reported the beneficial effect of statin treatment in 
lowering all-cause mortality in type 2 diabetes.  Older persons are under-represented in 
clinical trial data and it is therefore particularly important to obtain information on the 
potential improvement in life expectancy with statin use in older persons with type 2 
diabetes, as well as data on the relative impact of lipid lowering treatment in that age 
group. This will help in clarifying at a population-based level whether current guidelines 
Page 5 of 28
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
group.bmj.com on June 4, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
For peer review only
 
6 
 
should be applied to older persons, who may have had diabetes for an extended period of 
time. 
The present study addresses this information gap by exploring treatment modalities 
and cardiovascular and total mortality in older individuals with diabetes in the population-
based Age, Gene/Environment Susceptibility (AGES)-Reykjavik study. 
 
METHODS 
Study population 
Between 2002 and 2006 the AGES-Reykjavik study re-examined 5764 unselected 
survivors of the original cohort who had previously participated in the Reykjavik Study12. 
In the present study 5152 of these survivors are included, with a mean age of 77 years 
(range 66-96) and a median follow up time of 5.3 years until end of 2009. Informed 
consent was obtained from all study participants. The Reykjavik Study cohort originally 
comprised a random sample of 30 795 men and women born in 1907–1935, living in 
Reykjavik in 1967 that were invited to participate in a long-term prospective 
cardiovascular survey. A total of 19 381 attended, resulting in 71% recruitment rate 12.  
As part of the baseline examination in the AGES-Reykjavik study, a 
comprehensive questionnaire was administered. In order to eliminate any persons with type 
1 diabetes in the study, participants reporting onset of diabetes before the age of 40 were 
not included; neither were participants not completing their questionnaire or having 
incomplete data for other study variables included: 66 had missing data about diabetes 
history on questionnaire; 21 were considered to have diabetes of type 1; 78 had missing 
data on risk factors (cholesterol, systolic blood pressure, body mass index, triglycerides); 
447 had missing HbA1c.  Participants were asked to bring all medications and supplements 
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used in the previous 2 weeks to the clinic. All participants also had a fasting blood 
specimen drawn and analysed as documented below. 
The criteria used for type 2 diabetes diagnosis was either fasting serum glucose of 
≥7mmol/l at the visit to the clinic, based on the WHO recommendations from 199913, self-
reported diabetes in the questionnaire and/or use of diabetes medication. 
Blood samples were drawn after overnight fasting. Total cholesterol, HDL 
cholesterol, triglycerides, high sensitivity CRP, glucose and HbA1c were analysed on a 
Hitachi 912, using reagents from Roche Diagnostics and following the manufacturer’s 
instructions. LDL was calculated using the Friedewald equation14. 
Blood pressure was measured with a mercury sphygmomanometer with a large 
cuff, and the mean value of two consecutive blood pressure measurements was used in the 
analysis. Height and weight were measured and BMI calculated as kg/m2. 
Participants answered questions about frequency of moderate or vigorous physical 
activity, both current and in midlife.  Answers were categorized into never, rarely, 
occasionally, moderate or high frequency of participation.  In this study a binary variable 
for physical activity was used as an indicator for occasional or higher frequency of 
participation versus never or rarely participating. 
Answers about education were categorized into a binary variable: higher than 
secondary education versus secondary education or less. 
Information on the causes of death was based on data from a complete adjudicated 
registry of deaths available from the Icelandic National Roster  
(http://www.statice.is/Statistics/Population/Births-and-deaths). All-cause mortality was defined 
according to ICD 9-10. In this study we calculated an individual's time at risk from the date 
of participation in the baseline survey until the date of death from cardiovascular disease 
(ICD-9 and ICD-10: defined as in the SCORE project15) or from all causes, or until the end 
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of follow-up in the cohort. The information is collected from National Health System 
Records by the Icelandic Heart Association. 
The study was approved by the National Bioethics Committee in Iceland (VSN 00-
063) as well as the Institutional Review Board of the Intramural Research Program of the 
National Institute on Aging and the Data Protection Authority in Iceland.  
 
Statistical analyses  
Baseline characteristics of participants by sex and diabetic status in the AGES-Reykjavik 
study were compared using either linear or logistic regression with age adjustment. 
Skewed variables were log-transformed.  The Cox proportional hazards regression model 
was used to estimate mortality rates and hazard ratios for the effect of risk factors and 
statin use.  The time on study was used as the time scale. For hazard ratio estimates, an 
adjustment was made for age and sex in a simple model, and additionally for the following 
cardiovascular risk factors: cholesterol, HDL-cholesterol, systolic blood pressure, BMI, 
triglycerides, CRP, hypertensive medication, and current smoking. An additional analysis 
of mortality rates was done with adjustment for physical activity and education level.  A 
separate term was used in the survival models to represent subgroups, formed by diabetes, 
history of CHD and statin use.  The mortality rate was estimated from the average of the 
cumulative hazard function after a five-year follow-up and represented as the rate per 1000 
person-years.  The proportionality assumption for the hazard ratio associated with type 2 
diabetes was inspected graphically and by testing the significance of the interaction of type 
2 diabetes statuses with the logarithm of the follow-up of time analysed as a time-
dependent covariate. Significance testing was two-sided and based on a 5% probability 
level. We analysed the data using SAS/STAT® software, version 9.2. 
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RESULTS 
The mean age of the 5152 AGES-Reykjavik study participants was 77.0 (±5.8) years, with 
an age range of 66-96 years. The baseline characteristics in men and women with and 
without type 2 diabetes according to statin use are shown in Table 1. A higher percentage 
of individuals with type 2 diabetes were hypertensive than those without diabetes; they 
also had lower HDL-cholesterol but higher triglycerides and BMI, irrespective of statin 
use. Statin medication reduced the mean level of total and LDL-cholesterol similarly in 
those with and without diabetes, or by about 1.2 mmol/l in both men and women. In statin 
users CRP was lower by 0.30 mg/l in men and 0.50 mg/l in women without diabetes and 
0.80 and 1.05 mg/l respectively in those with diabetes. The prevalence of coronary heart 
disease estimated from hospital records in persons without diabetes using statins, was 
71.1% in men and 34.4% in women compared to 7.9% and 2.2% respectively in those not 
using statins. In individuals with diabetes the coronary heart disease prevalence was 59.4% 
in men and 24.2% in women using statins, compared to 14.8% and 8.6% respectively in 
those not on statins. Over 93% of all statin users were hypertensive compared to 78% of 
non-statin users. 
The prevalence of type 2 diabetes and use of glucose lowering treatment in men 
and women is shown in Table 2. About 16% of men and 9.5% of women in the cohort had 
type 2 diabetes and the proportion of persons with diabetes undiagnosed at baseline was 
31%. In the group with previously diagnosed type 2 diabetes, 23% of the men and 35% of 
the women controlled their blood sugar level with diet only. As shown in Table 2, less than 
7% of persons with diagnosed diabetes were simultaneously taking 3 or 4 drugs for 
lowering blood glucose. For participants with a prior diagnosis of diabetes, the average 
time from diagnosis at baseline assessment was just over 10 years. 
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Effect of statins on cardiovascular and all-cause mortality     
The five-year average cardiovascular disease mortality and all-cause mortality rates for 
those with and without diabetes are shown in Figure 1. Mortality rate is estimated 
according to statin use and prevalence of coronary heart disease, adjusted to age 75, sex 
and the mean levels of cardiovascular risk factors (cholesterol, HDL-cholesterol, systolic 
blood pressure, BMI, triglycerides, hypertensive medication and current smoking) within 
each cohort. About 26% of men and 16% of women without diabetes and about 35% in 
both sexes with diabetes were statin users. Statin medication was administered to 69.2% of 
persons with prevalent coronary heart disease and known diabetes compared to 31.6% of 
those with known diabetes but without coronary heart disease (Supplement Table 1). 
For individuals with diabetes and prevalent coronary heart disease, statin use was 
associated with a significantly lower rate of cardiovascular disease mortality (Figure 1a) 
compared to those not using statins, or 11.3 vs. 24.6 per 1000 person years. This amounts 
to 54% (95% confidence interval 14% to 75%) lower mortality rate in statin users. 
Similarly statin use was associated with an all-cause mortality rate of 27.8 vs. 63.3 per 
1000 person years when comparing the same two groups (Figure 1b), amounting to 55% 
(31% to 71%) lower mortality rate in statin users.  In individuals with diabetes but without 
coronary heart disease, the rate was 48% (1% to 73%) lower for cardiovascular disease 
mortality and 52% (26% to 69%) lower for all-cause mortality in the group using statins 
compared to non-statin users. Combining the groups the hazard of cardiovascular disease 
mortality was 50% lower in statin users compared to non-statin users and all-cause 
mortality was 53% lower (Supplement Table 2). 
Statin use was associated with 16% (-24% to 43%) lower cardiovascular mortality 
rate in individuals without diabetes as shown in Figure 1, albeit not statistically significant. 
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For all-cause mortality statin users had 30% (11% to 46%) lower mortality rate than in 
non-statin users.  
The effect of statins was not modified by the level of HbA1c, the use of oral 
hypoglycaemic or hypertensive medication, or whether the diabetes was prevalent or newly 
diagnosed (Supplement Figures 1 and 2).  
An additional analysis of mortality rates with adjustment for current physical activity 
and education level did not have any material effect on the results or the conclusions 
drawn from the data.  The additionally adjusted mortality rates are shown in 
Supplement Figure 3. 
The dramatic effect of statin medication use on mortality rate in persons with 
diabetes is also reflected in the hazard ratios for the relative risk of cardiovascular and all-
cause mortality in individuals with diabetes compared to those without as shown in Table 
3. In persons with diabetes and prevalent coronary heart disease not on statins, the relative 
risk of dying from cardiovascular disease was 3.33 (2.05 to 5.50) when compared to those 
without diabetes, after adjusting for age, sex and cardiovascular risk factors. The 
individuals treated with statins, however, had a relative risk of 1.51 (0.83 to 2.75). In 
persons with diabetes but without coronary heart disease not on statins, the relative risk 
was 1.40 (1.03 to 1.89) compared to 0.71 (0.31 to 1.62) for those on statins.  Adding CRP 
to the risk factor adjustment showed minimal attenuation of the hazard ratios (Table 3). 
This implies that the protective effect of statins is not solely attributable to the effect on 
these cardiovascular risk factors. 
 
DISCUSSION 
The major finding in our population-based AGES-Reykjavik study of older individuals 
with diabetes is the marked improvement in survival associated with statin medication 
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when compared to those not receiving statins, both with respect to cardiovascular and all-
cause mortality. This is independent of prevalent coronary heart disease or glucose-
lowering treatment, reducing the mortality rate in individuals with diabetes to a level 
comparable to those without diabetes.  
Statin medication in diabetes has increased gradually during the last decade. Data 
from the U.K. General Practice Research Database showed an increase in statin use from 
about 5% in 1996 to 63.5% in women and 71.0% in men in 200510, which was associated 
with hazard ratios of mortality of 0.29 in women and 0.34 in men in the first two years 
following diagnosis of diabetes. Similarly, in Denmark, only 7% of patients receiving 
glucose-lowering medication also received statins in 1997, but this had increased to 62% in 
200711; information on mortality in that study is however lacking. In our cohort of older 
persons with diabetes the prevalence of statin medication use was 35% overall. In those 
with known diabetes but without coronary heart disease the prevalence of statin medication 
use was 31.6%, but 11.6% in the newly diagnosed without coronary heart disease. One 
may speculate if this low prevalence of statin use is due to Icelandic physicians’ 
unawareness of results from recent clinical trials or simply their belief that the evidence 
does not apply to older patients in general. 
It is of course well recognised that statin treatment favourably impacts vascular 
event rates in both those with and without diabetes. In the Heart Protection Study2 for 
example it was concluded that 40 mg of simvastatin daily would probably reduce the rate 
of first major vascular event by about a third. Similarly a two-year treatment period with 
atorvastatin in type 2 diabetes in the CARDS study reduced the death rate by 27%, 
prompting an early termination of the trial16. The authors concluded that lipid-lowering 
treatment should at least receive the same attention as glycemic and blood pressure control 
in type 2 diabetes patients without a history of cardiovascular disease, which is in harmony 
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with current clinical guidelines. Aggressive multifactorial treatment of high-risk 
individuals with type 2 diabetes has been shown to be important9, and may also be 
appropriate for persons diagnosed above the age of 70. Recent results from several large 
studies17, 18 have, however, indicated that caution may be needed as regards aggressive 
glucose lowering treatment in those with long-established coronary heart disease and 
diabetes of long duration. In our study, statin use at baseline, but not use of glucose-
lowering medication, is associated with the marked reduction of cardiovascular and total 
mortality rate, reducing mortality in those with diabetes to a level similar to those without 
diabetes.   
Statin medication under the rigors of controlled study conditions in selected 
individuals has thus been shown to be helpful2, 4 5. The novelty of our study is that statin 
medication also is very likely to be important in older persons in the community, persons 
which may or may not fit the stringent criteria of normality imposed for inclusion into 
randomised clinical trials.   
Recently a large meta-analysis1 demonstrated that the increased cardiovascular 
mortality seen in type 2 diabetes is not explained by conventional cardiovascular risk 
factors. This suggests that the effect of the statins on cardiovascular mortality seen in our 
population-based cohort may reach beyond the statins' effect on cholesterol levels, possibly 
by reducing the damaging effect of inflammatory agents19, 20. Inflammation as measured by 
CRP, however, does not appear to be the explanation in our study, as adjusting for CRP in 
the risk models did not attenuate the relative risk although those on statins had markedly 
lower CRP. This warrants further study. 
The prevalence of diabetes in Iceland is changing in the same fashion as in other 
western societies21. Furthermore, the Icelandic population is similar to other western 
populations with respect to cardiovascular morbidity and mortality22, and our results are 
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therefore applicable to other Caucasian populations. Thus, considerable additional benefit 
can be expected by adhering to the current guidelines on statin use in treating individuals 
with diabetes, also in the older age-groups.  
In summary, we have estimated the risk of death from cardiovascular disease and 
from all causes in a population-based cohort of older persons with type 2 diabetes. The 
main finding is that statin use, irrespective of glucose-lowering and antihypertensive 
medication, eliminates the difference in the mortality rate of older persons with type 2 
diabetes, compared to those without diabetes. Our study suggests that treatment with 
statins is paramount in the multifaceted management of type 2 diabetes. Strict adherence to 
the current guidelines is therefore of key importance for older persons with diabetes, 
regardless of the presence or absence of cardiovascular disease or the level of glucose or 
blood pressure control.  
Our results urgently call for other population-based studies with comparable 
information to confirm the effect of statin use on mortality in individuals with type 2 
diabetes. 
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Table 1. Baseline characteristics according to statin use in men and women without and with type 2 
diabetes (T2D). The AGES-Reykjavik study from 2002-2006. 
 
 
Men    Women    
Variables Statins no  Statins yes  Statins no  Statins yes  
(mean ± SD, IQR or %) without T2D with T2D without T2D with T2D without T2D with T2D without T2D with T2D 
(number) (1357) (230) (477) (128) (2237) (186) (442) (95) 
Age in years 77.4  (±5.8) 77.9  (±6.1)  76.0  (±4.8)  75.5  (±4.4)  77.0  (±6.1) 78.7  (±6.0) ***  76.1  (±4.8)  76.3  (±4.5) 
Cholesterol mmol/l 5.57  (±0.93) 5.38  (±0.98) ** 4.32  (±0.82)  4.14  (±0.84) * 6.19 (±1.05) 5.97  (±1.01) **  4.96  (±0.83) 4.67  (±0.94) ** 
HDL cholesterol mmol/l 1.46  (±0.40) 1.26  (±0.34) *** 1.40  (±0.37)  1.26  (±0.33) ***  1.75  (±0.45) 1.53  (±0.41) ***  1.70  (±0.40) 1.48  (±0.41) ***  
LDL cholesterol mmol/l 3.61  (±0.85) 3.40  (±0.89) **  2.38  (±0.67)  2.21  (±0.68) **  3.90  (±0.98) 3.73  (±0.91) *  2.71  (±0.72) 2.41  (±0.70) ***  
TG mmol/l, median (IQR) 0.97  (0.56) 1.33  (0.83) ***  1.01  (0.65) 1.29  (0.98) ***  1.04  (0.63) 1.38  (0.85) *** 1.11  (0.67) 1.57 (0.85) ***  
CRP mg/l, median (IQR)  1.90 (2.70) 2.20 (3.53) ** 1.60  (2.20)  1.40  (2.10)  2.00 (3.20) 3.15 (5.65) ***  1.50  (2.10) 2.10  (3.30) * 
BMI kg/m2 26.4  (±3.7) 28.3  (±4.2) *** 27.0  (±3.7)  28.4  (±3.7) ***  27.0  (±4.9) 29.0  (±5.5) ***  26.8  (±4.0) 30.2  (±5.1) *** 
Systolic BP mm Hg 142.9  (±20.6) 141.1  (±20.7) 144.1  (±20.3) 148.2  (±19.6) ***  142.2  (±21.0) 143.3 3  (±21.8)  143.3  (±20.2) 143.6  (±19.7)   
Diastolic BP mm Hg 77.0  (±9.4) 74.7  (±10.8) ** 74.4  (±9.7)  74.6  (±10.3)  72.6  (9.3) 70.5  (±10.5)* 71.6  (±10.2) 69.7  (±8.9)  
Hypertension %† 73.5 88.7 *** 91.6 95.3 78.9 88.7 ** 92.5 95.8  
Hypertensive  medication % 50.0 75.2 *** 85.5 87.5 58.7 79.6***  84.6 90.5  
Glucose lowering medication - 46.1 - 64.1 - 36.6 - 64.2 
CHD prevalence %‡ 7.9 14.8** 71.1 59.4* 2.2 8.6***  34.4 24.2* 
Family history MI % 30.1 39.1 ** 45.2 41.4 40.2 51.6 ** 56.7 53.7 
Physical activity in  midlife % 51.0 43.9  54.3 45.3  47.1 40.9  50.7 36.8*  
Physical activity current % 39.6 27.4*** 45.3 35.2* 31.3 26.3 34.2 16.8* 
Education, more than secondary% 30.0 27.4 29.8 28.9 21.9 20.4 17.2 16.8 
Smoking % 11.9 12.2  9.0 9.4 12.4 10.2  12.9 9.5 
Haemoglobin A1c  % 5.54 (±0.33) 6.38 (±0.88) ***  5.58 (±0.32) 6.55 (±0.79) ***  5.61 (±0.33) 6.32 (±0.95) ***  5.64 (±0.34) 6.58 (±0.88) *** 
Glucose mmol/l 5.57 (±0.50) 7.95 (±2.09) ***  5.58 (±0.53) 7.92 (±2.19) ***  5.44 (±0.51) 7.60 (±2.00) ***  5.41  (±0.52) 7.97  (±2.38) ***  
Significance estimates for age-adjusted comparison between those with and without T2D and not using statins (no) and statin users (yes): *p<.05; **p<.01; *** p<.001.  
†Hypertensive are those with systolic BP>140 mmHg, diastolic BP>90 mmHG or on hypertensive medication. 
 
‡Prevalence from history of MI, PCI, and CABG in hospital records. 
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Table 2.  Prevalence of type 2 diabetes (T2D) and glucose lowering treatment in the 
AGES-Reykjavik study 2002-2006. 
AGES-Reykjavik study   Men Women Men and 
women 
% of total T2D
Total T2D at baseline % (n) 16.3 (358) 9.5 (281) 12.4 (639) 100 
Diagnosed at study entry % (n) 5.1 (113) 2.8 (84) 3.8 (197) 31 
With prevalent T2D at study entry % (n) 11.2 (245) 6.7 (197) 8.6 (442) 69 
Mean T2D duration in years (±SD)   10.7 (±10.0)  
    
 
Glucose lowering treatment in prevalent 
T2D 
   
 
        on special diet only % (n) 23.3 (57) 34.5 (68)   
        on diabetic medication % (n) 76.7 (188) 65.5 (129)   
thereof using 1 drug % (n)  43.7 (107) 40.1 (79)  
 
"     using 2 drugs % (n) 25.7 (63)  19.8 (39)  
 
"     using 3 drugs % (n) 6.9 (17) 4.6 (9)  
 
"     using 4 drugs % (n) 0.4 (1) 1.0 (2)  
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Table 3.  Hazard ratios (HR) for the relative risk of cardiovascular disease (CVD) mortality and all cause mortality in people with type 2 diabetes (T2D) 
compared to all non-diabetics according to prevalent coronary heart disease (chd) and statin use*.  The AGES-Reykjavik study from 2002-2006.   
 
  
 
 Adjusted for age and sex  Adjusted for age, sex,  Adjusted for age, sex,  
 
   and †CVD risk factors †CVD risk factors and CRP 
 
    
 
   
HR                      95% CI 
                 HR              95% CI        HR               95% CI 
Death from CVD     
     
All T2D  1.71 (1.35 to 2.17) 1.48 (1.15 to 1.90) 1.45 (1.13 to 1.86) 
According to chd and statin use:       
T2D with chd not on statins  4.71 (2.93 to 7.58) 3.33 (2.02 to 5.50) 3.20 (1.94 to 5.29) 
T2D with chd on statins  1.92 (1.08 to 3.43) 1.51 (0.83 to 2.75) 1.55 (0.85 to 2.82) 
T2D without chd and not on statins  1.53 (1.14 to 2.05) 1.40 (1.03 to 1.89) 1.34 (0.99 to 1.82) 
T2D without chd and on statins  0.83 (0.37 to 1.85) 0.71 (0.31 to 1.62) 0.75 (0.33 to 1.69) 
 
      
Death from all causes       
 
      
All T2D  1.44  (1.22 to 1.69) 1.35 (1.14 to 1.61) 1.32 (1.11 to 1.57) 
According to chd and statin use:       
T2D with chd not on statins 3.48 (2.43 to 4.99) 2.88 (1.98 to 4.18) 2.72 (1.87 to 3.95) 
T2D with chd on statins  1.61 (1.10 to 2.37) 1.34 (0.90 to 1.99) 1.37 (0.92 to 2.04) 
T2D without chd not on statins  1.34 (1.09 to 1.64) 1.34 (1.08 to 1.64) 1.27 (1.03 to 1.57) 
T2D without chd on statins  0.77 (0.46 to 1.28) 0.70 (0.42 to 1.17) 0.73 (0.44 to 1.23) 
*Individuals on statin medication are identified as on statins, those not on statin medication as not on statins. 
†CVD risk factors: cholesterol, HDL-cholesterol, systolic blood pressure, BMI, triglycerides, hypertensive medication, and current smoking.  
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Figure 1. a) Cardiovascular disease (CVD) mortality rate and b) all cause mortality rate 
per 1000 person years for subjects without type 2 diabetes (not T2D) and with type 2 
diabetes (T2D) according to statin use and prevalent coronary heart disease (chd).  Rates 
have been adjusted to age 75, sex and the mean levels of cardiovascular risk factors 
(cholesterol, HDL-cholesterol, systolic blood pressure, BMI, triglycerides, hypertensive 
medication and current smoking) within each cohort.  Follow up was through 2009 (a 
median period of 5.3 years) for the AGES-Reykjavik study. The vertical lines represent the 
mortality rate of all without diabetes (not T2D, N=4513) 
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Section/Topic Item # Recommendation Reported on page # 
(a) Indicate the study’s design with a commonly used term in the title or the abstract 1 Title and abstract 1 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 5 
Objectives 3 State specific objectives, including any pre-specified hypotheses 5 
Methods  
Study design 4 Present key elements of study design early in the paper 6 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data 
collection 
6 
(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe 
methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 
6 Participants 6 
(b) Cohort study—For matched studies, give matching crit ria and number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per case 
Not applicable 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic 
criteria, if applicable 
8-10 
Data sources/ measurement 8*  For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one group 
6-7 
Bias 9 Describe any efforts to address potential sources of bias Not done 
Study size 10 Explain how the study size was arrived at 6-7 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen 
and why 
7-8 
(a) Describe all statistical methods, including those used to control for confounding 7-8 
(b) Describe any methods used to examine subgroups and interactions Separate terms for 
subgroups in 
statistical models 
Statistical methods 12 
(c) Explain how missing data were addressed 6 
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(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy 
6 
(e) Describe any sensitivity analyses Not done 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-up, and analysed 
8 
  (b) Give reasons for non-participation at each stage 13 
  (c) Consider use of a flow diagram  
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and 
potential confounders 
8-9 
  (b) Indicate number of participants with missing data for each variable of interest 6 
  (c) Cohort study—Summarise follow-up time (eg, average and total amount) 6 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 8-10 
  Case-control study—Report numbers in each exposure category, or summary measures of exposure  
  Cross-sectional study—Report numbers of outcome events or summary measures  
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% 
confidence interval). Make clear which confounders were adjusted for and why they were included 
Table 3 
  (b) Report category boundaries when continuous variables were categorized  
  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Figure 1 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses All analyses are by 
subgroups 
Discussion  
Key results 18 Summarise key results with reference to study objectives 11-12 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction 
and magnitude of any potential bias 
13 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results 
from similar studies, and other relevant evidence 
12-13 
Generalisability 21 Discuss the generalisability (external validity) of the study results 13-14 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on 
which the present article is based 
14 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
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Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
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